MTOR Regulates Cell Survival After Etoposide Treatment in Primary AML Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2005 Sep 10

PMID 16150937

Citations 78

Authors

Qing Xu

James E Thompson

Martin Carroll

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia cells have constitutive activation of phosphatidylinositol 3(PI3) kinase and require PI3 kinase activation for survival; however, the function of the PI3 kinase pathway in the survival of leukemic cells is poorly defined. We have studied the role of one PI3 kinase substrate, mTOR (mammalian target of rapamycin), in primary leukemic cells. In initial experiments, we have defined a novel growth medium that improves survival of acute myeloid leukemia (AML) blasts in long-term suspension culture and the survival of leukemic stem cells in short-term cultures. Inhibition of mTOR using rapamycin leads to a modest decrease in cell survival after 2 days of incubation with more significant decrease in survival after 7 days of culture. However, when rapamycin is added to etoposide in 2-day cultures, there is a dramatic increase in the cytotoxicity of etoposide against AML blasts. Furthermore, etoposide consistently decreased the engraftment of AML cells in nonobese diabetic/severe combined immunodeficient (NOD/SCID) animals, and this effect was enhanced by coincubation with rapamycin, demonstrating that mTOR regulates survival of AML stem cells after etoposide treatment. These results suggest that rapamycin in combination with etoposide-based chemotherapy may be efficacious in the treatment of AML.

Citing Articles

Rapamycin increases leukemia cell sensitivity to chemotherapy by regulating mTORC1 pathway-mediated apoptosis and autophagy.

Xu J, Zong S, Sheng T, Zheng J, Wu Q, Wang Q Int J Hematol. 2024; 119(5):541-551.

PMID: 38530586 DOI: 10.1007/s12185-024-03732-0.

A Phase I Trial of Sirolimus with "7&3" Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Palmisiano N, Jeschke G, Wilde L, Alpdogan O, Carabasi M, Filicko-OHara J Cancers (Basel). 2023; 15(21).

PMID: 37958304 PMC: 10650097. DOI: 10.3390/cancers15215129.

Activation of orphan receptor GPR132 induces cell differentiation in acute myeloid leukemia.

Yi C, He J, Huang D, Zhao Y, Zhang C, Ye X Cell Death Dis. 2022; 13(11):1004.

PMID: 36437247 PMC: 9701798. DOI: 10.1038/s41419-022-05434-z.

Targeting metabolism: A potential strategy for hematological cancer therapy.

Tang X, Chen F, Xie L, Liu S, Mai H World J Clin Cases. 2022; 10(10):2990-3004.

PMID: 35647127 PMC: 9082716. DOI: 10.12998/wjcc.v10.i10.2990.

Exploring the Metabolic Landscape of AML: From Haematopoietic Stem Cells to Myeloblasts and Leukaemic Stem Cells.

Mesbahi Y, Trahair T, Lock R, Connerty P Front Oncol. 2022; 12:807266.

PMID: 35223487 PMC: 8867093. DOI: 10.3389/fonc.2022.807266.

References

Kahan B, Julian B, Pescovitz M, Vanrenterghem Y, Neylan J . Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation. 1999; 68(10):1526-32. DOI: 10.1097/00007890-199911270-00016. View

Bierer B, Mattila P, Standaert R, Herzenberg L, Burakoff S, Crabtree G . Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A. 1990; 87(23):9231-5. PMC: 55138. DOI: 10.1073/pnas.87.23.9231. View

Aoki M, Blazek E, Vogt P . A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A. 2001; 98(1):136-41. PMC: 14557. DOI: 10.1073/pnas.98.1.136. View

Levis M, Tse K, Smith B, Garrett E, Small D . A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood. 2001; 98(3):885-7. DOI: 10.1182/blood.v98.3.885. View

Coffer P, Woodgett J . Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991; 201(2):475-81. DOI: 10.1111/j.1432-1033.1991.tb16305.x. View

Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U . Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest. 1993; 92(4):1736-44. PMC: 288334. DOI: 10.1172/JCI116761. View

Sabers C, Martin M, Brunn G, Williams J, Dumont F, Wiederrecht G . Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem. 1995; 270(2):815-22. DOI: 10.1074/jbc.270.2.815. View

Blommaart E, Luiken J, Blommaart P, Van Woerkom G, Meijer A . Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem. 1995; 270(5):2320-6. DOI: 10.1074/jbc.270.5.2320. View

Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K . Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996; 10(12):1911-8. View

10.

Bonnet D, Dick J . Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3(7):730-7. DOI: 10.1038/nm0797-730. View

11.

Miller D, Fricker G, Drewe J . p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther. 1997; 282(1):440-4. View

12.

Ailles L, Gerhard B, Hogge D . Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood. 1997; 90(7):2555-64. View

13.

Yamaguchi H, Ishii E, Tashiro K, Miyazaki S . Role of umbilical vein endothelial cells in hematopoiesis. Leuk Lymphoma. 1998; 31(1-2):61-9. DOI: 10.3109/10428199809057585. View

14.

Ailles L, Gerhard B, Kawagoe H, Hogge D . Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999; 94(5):1761-72. View

15.

Stone R, DeAngelo D, Klimek V, Galinsky I, Estey E, Nimer S . Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2004; 105(1):54-60. DOI: 10.1182/blood-2004-03-0891. View

16.

Tee A, Blenis J . mTOR, translational control and human disease. Semin Cell Dev Biol. 2005; 16(1):29-37. DOI: 10.1016/j.semcdb.2004.11.005. View

17.

Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas V . Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2004; 105(6):2527-34. DOI: 10.1182/blood-2004-06-2494. View

18.

Beuvink I, Boulay A, Fumagalli S, Zilbermann F, Ruetz S, OReilly T . The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell. 2005; 120(6):747-59. DOI: 10.1016/j.cell.2004.12.040. View

19.

Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington C . AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A. 2001; 98(18):10398-403. PMC: 56972. DOI: 10.1073/pnas.171321298. View

20.

Ayton P, Cleary M . Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001; 20(40):5695-707. DOI: 10.1038/sj.onc.1204639. View